Screening for SNPs and haplotypes in the CYP3A7 gene in Chinese populations

Pharmacogenomics

Volumn 8, Issue 6, 2007, Pages 559-566

  Du, Jing ^a,b   Shi, Yongyong ^a,b   Zhang, Aiping ^a,b   Wang, Lei ^a,b   Xuan, Jiekun ^a,b   He, Guang ^a,b   Xu, Lingyun ^c   Xu, Mingsheng ^d   Shu, Anli ^e   Yu, Lan ^a,b   Li, Xingwang ^a,b   Meng, Junwei ^a,b   Feng, Guoyin ^f   Xing, Qinghe ^a,b   He, Lin ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c WANNAN MEDICAL COLLEGE   (China)

^d Anhui Institute of Parasitic Diseases   (China)

^e HUAIHUA MEDICAL COLLEGE   (China)

^f SHANGHAI MENTAL HEALTH CENTER   (China)

Author keywords

Chinese; CYP3A7; Genetic polymorphism; Halotype; Intra ethnic difference; Minority Chinese

Indexed keywords

ADENINE; CYTOCHROME P450 3A7; CYTOSINE; DNA; GUANINE; THYMINE;

ADULT; ALLELE; ARTICLE; CHINESE; CONTROLLED STUDY; ETHNIC DIFFERENCE; EXON; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC SCREENING; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN EXPERIMENT; INDIVIDUALIZATION; MALE; NORMAL HUMAN; NUCLEIC ACID BASE SUBSTITUTION; POPULATION GENETICS; RACE DIFFERENCE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC SCREENING; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; SUBSTRATE SPECIFICITY;

EID: 34250690424     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.6.559     Document Type: Article

References (23)

1. Eichelbaum M, Burk O: CYP3A genetics in drug metabolism. Nat. Med. 7, 285-287 (2001).
2. Gonzalez FJ, Schmid BJ, Umeno M et al.: Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. DNA 7, 79-86 (1988).
3. Domanski TL, Finta C, Halpert JR, Zaphiropoulos PG: cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol. Pharmacol. 59, 386-392 (2001).
4. Thummel KE, Wilkinson GR: In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol. 38, 389-430 (1998).
5. Paine MF, Khalighi M, Fisher JM et al.: Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther. 283, 1552-1562 (1997).
6. Wrighton SA, VandenBranden M, Ring BJ: The human drug metabolizing cytochromes P450. J. Pharmacokinet. Biopharm. 24, 461-473 (1996).
7. Nebert DW, Russell DW: Clinical importance of the cytochromes P450. Lancet 360, 1155-1162 (2002).
8. Tateishi T, Watanabe M, Moriya H, Yamaguchi S, Sato T, Kobayashi S: No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. Biochem. Pharmacol. 57, 935-939 (1999).
9. Tateishi T, Nakura H, Asoh M et al.: A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. Life Sci. 61, 2567-2574 (1997).
10. Shimada T, Yamazaki H, Mimura M et al.: Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. Drug Metab. Dispos. 24, 515-522 (1996).
11. Ohmori S, Nakasa H, Asanome K et al.: Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells. Biochim. Biophys. Acta 1380, 297-304 (1998).
12. Lee AJ, Conney AH, Zhu BT: Human cytochrome P450 3A7 has a distinct high catalytic activity for the 16α-hydroxylation of estrone but not 17β-estradiol. Cancer Res. 63, 6532-6536 (2003).
13. Marill J, Capron CC, Idres N, Chabot GG: Human cytochrome P450s involved in the metabolism of 9-cis- and 13-cis-retinoic acids. Biochem. Pharmacol. 63, 933-943 (2002).
14. Leeder JS, Gaedigk R, Marcucci KA et al.: Variability of CYP3A7 expression in human fetal liver. J. Pharmacol. Exp. Ther. 314, 626-635 (2005).
15. Rodriguez-Antona C, Jande M, Rane A, Ingelman-Sundberg M: Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers. Clin. Pharmacol. Ther. 77, 259-270 (2005).
16. Wood AJ: Racial differences in the response to drugs - pointers to genetic differences. N. Engl. J. Med. 344, 1394-1396 (2001).
17. Ozdemir V, Kalow W, Tothfalusi W, Bertilsson L, Endrenyi L, Graham JE: Multigenic control of drug response and regulatory decision-making in pharmacogenomics: the need for an upper-bound estimate of genetic contributions. Curr. Pharmacogenomics 3, 53-71 (2005).
18. Mirghani RA, Sayi J, Aklillu E et al.: CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenet. Genomics 16, 637-645 (2006).
19. Zhang JP, Zhou SF, Chen X, Huang M: Determination of intra-ethnic differences in the polymorphisms of thiopurine S-methyltransferase in Chinese. Clin. Chim. Acta 365, 337-341 (2006).
20. Dudbridge F: Pedigree disequilibrium tests for multilocus haplotypes. Genet. Epidemiol. 25, 115-121 (2003).
21. Ozdemir V, Kalowa W, Tang BK et al.: Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10, 373-388 (2000).
22. Judson R, Stephens JC, Windemuth A: The predictive power of haplotypes in clinical response. Pharmacogenomics 1, 15-26 (2000). [Abstract]
23. Halushka MK, Fan JB, Bentley K et al.: Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat. Genet. 22, 239-247 (1999).